|1.||Brown, Sandra M: 3 articles (06/2005 - 08/2003)|
|2.||Cambron, Melissa: 2 articles (04/2014 - 10/2011)|
|3.||Crevits, Luc: 2 articles (04/2014 - 10/2011)|
|4.||Maertens, Heidi: 2 articles (04/2014 - 10/2011)|
|5.||Hsiao, Chih-Hsien: 2 articles (09/2006 - 06/2006)|
|6.||Chen, Jiann-Torng: 2 articles (09/2006 - 06/2006)|
|7.||Lu, Da-Wen: 2 articles (09/2006 - 06/2006)|
|8.||Chen, Po-Liang: 2 articles (09/2006 - 06/2006)|
|9.||Freedman, Kenn A: 2 articles (06/2005 - 08/2003)|
|10.||Bursztyn, Lulu L C D: 1 article (09/2015)|
10/01/1995 - "Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. "
10/01/1997 - "This study describes our long-term experience with apraclonidine 0.5% in the treatment of chronic glaucoma in clinical practice. "
12/01/1995 - "To evaluate the effect of the chronic use of apraclonidine 0.5% on the intraocular pressure (IOP) of patients with glaucoma; also, to study the side effect profile of this drug when used chronically. "
06/01/2009 - "In all, 115 eyes of 75 pediatric glaucoma patients received apraclonidine 0.5% drops, for a total 179 treatment sessions. "
06/01/2009 - "Here we evaluate the safety of topical apraclonidine 0.5% when used in children with glaucoma. "
|2.||Open-Angle Glaucoma (Glaucoma, Open Angle)
04/01/1999 - "Apraclonidine 0.5% appears to be effective in reduction of post-dilated IOP increases in patients with chronic open-angle glaucoma."
04/01/1999 - "The purpose of this study is to determine the effectiveness of 0.5% apraclonidine in reversing IOP increases after pupillary dilation in patients with chronic open-angle glaucoma. "
11/01/1997 - "This study consisted of 231 consecutive eyes of patients with primary open-angle glaucoma undergoing ALT: 70 eyes (30%) were started on a regimen including chronic apraclonidine 0.5% use (group A) and 161 eyes (70%) were started on a regimen without chronic apraclonidine 0.5% use (group B). "
04/01/1999 - "Apraclonidine 1.0% has been shown to reverse the potential intraocular pressure (IOP) increase after pupil dilation IOP increases in patients with chronic open-angle glaucoma. "
04/01/1999 - "Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma."
|3.||Horner Syndrome (Horner's Syndrome)
09/01/2006 - "Efficacy of apraclonidine 0.5% in the diagnosis of Horner syndrome in pediatric patients under low or high illumination."
09/01/2006 - "The application of apraclonidine in pediatric patients is safe and effective in the diagnosis of Horner syndrome. "
06/01/2006 - "The application of 0.5% apraclonidine in pediatric patients is safe and effective in the diagnosis of Horner syndrome."
03/01/2010 - "A review of all reported cases of apraclonidine testing in Horner syndrome suggests that this is a promising diagnostic adjunct that must be validated in larger studies."
01/01/2009 - "This study aimed at developing through three clinical cases, the usefulness of topical apraclonidine 0.5% to confirm a diagnosis of Bernard-Horner syndrome. "
09/01/1993 - "Long-term therapy for some patients may be inhibited by ocular allergy for which there was a higher incidence to the 0.5% apraclonidine solution than to the 0.25% solution in this study. "
04/01/2012 - "No differences were observed between the preoperative [0.40 (SD 0.07)] and 1-month basal values [0.38 (SD 0.07)], and instillation of apraclonidine no longer induced a hypersensitivity response. "
06/01/2000 - "Forty-five patients were identified with a significant allergic reaction to apraclonidine that resulted in drug discontinuation. "
06/01/2000 - "A retrospective chart review was performed to identify patients who had demonstrated an allergic reaction to apraclonidine of sufficient severity to result in drug discontinuation. "
01/01/1998 - "For the 10 patients rechallenged with apraclonidine, the mean time to allergy was 13.6 +/- 10.2 days (range 3-32 days). "
|5.||Ocular Hypertension (Glaucoma, Suspect)
04/01/1999 - "We studied the acute effects of the ocular hypotensive drug, apraclonidine (AP), on intraocular pressure (IOP) and aqueous humor dynamics of anesthetized rats during infusion-induced ocular hypertension. "
09/01/1993 - "Apraclonidine effectively lowers IOP associated with open-angle glaucoma or ocular hypertension; these pilot results will need to be confirmed by a larger pivotal study. "
07/01/1991 - "The short-term additive effect and side effects of adding 1% apraclonidine hydrochloride to nonselective beta-blockers were investigated in 21 patients with ocular hypertension or early primary open-angle glaucoma. "
09/01/1993 - "To compare the safety and efficacy of apraclonidine ophthalmic solution 0.25% and 0.5% (both given 3 times daily) to timolol maleate (0.5%) given twice daily, in primary open-angle glaucoma or ocular hypertension. "
10/01/1991 - "Seventeen patients (15 with primary open-angle glaucoma, 1 with pigmentary glaucoma, and 1 glaucoma suspect) on long-term timolol treatment in both eyes received a single dose of apraclonidine in one eye and a placebo in the other. "
|2.||Cocaine (Cocaine HCl)
|4.||Clonidine (ST 155)
|6.||Ophthalmic Solutions (Eye Drops)
|10.||Excitatory Amino Acids
|3.||Laser In Situ Keratomileusis (LASIK)